Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (80,883,000)	$ 1,404,000	$ (28,166,000)	$ (6,703,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Gain on sales		(679,000)	(49,904,000)	(679,000)
Impairment charges			80,887,000	7,607,000
Straight-line rents and expenses, net			(285,000)	1,304,000
Provision for doubtful accounts			606,000	1,010,000
Depreciation and amortization	9,510,000	10,035,000	30,978,000	38,208,000
Amortization of intangible lease liabilities, net	(268,000)	(299,000)	(807,000)	(1,065,000)
Expense relating to share-based compensation, net			2,509,000	2,753,000
Amortization of deferred financing costs			1,203,000	969,000
Changes in operating assets and liabilities, net of effects of acquisitions and dispositions:
Rents and other receivables			(862,000)	(3,381,000)
Prepaid expenses and other			(4,771,000)	(12,280,000)
Accounts payable and accrued liabilities			931,000	(1,574,000)
Net cash provided by operating activities			32,319,000	26,169,000
INVESTING ACTIVITIES
Expenditures for real estate improvements			(19,612,000)	(29,815,000)
Net proceeds from sales of real estate			104,497,000	5,013,000
Contributions to unconsolidated joint venture			(3,193,000)
Net cash provided by (used in) investing activities			81,692,000	(24,802,000)
FINANCING ACTIVITIES
Repayments under revolving credit facility			(188,000,000)	(83,100,000)
Advances under revolving credit facility			79,000,000	98,000,000
Repayment of term note			(100,000,000)
Termination payment related to interest rate swap			(503,000)
Mortgage proceeds			114,000,000
Mortgage repayments			(825,000)	(797,000)
Payments of debt financing costs			(3,261,000)	(305,000)
Noncontrolling interests:
Distributions to limited partners			(15,000)	(37,000)
Redemption of OP units			(8,000)
Common stock sales less issuance expenses, net			4,000	11,000
Preferred stock dividends			(8,064,000)	(8,064,000)
Distributions to common shareholders			(3,015,000)	(6,254,000)
Net cash used in financing activities			(110,687,000)	(546,000)
Net increase in cash, cash equivalents and restricted cash			3,324,000	821,000
Cash, cash equivalents and restricted cash at beginning of period			1,637,000	2,747,000
Cash, cash equivalents and restricted cash at end of period	4,961,000	3,568,000	4,961,000	3,568,000
Reconciliation to consolidated balance sheets:
Cash and cash equivalents	4,731,000	3,568,000	4,731,000	3,568,000
Restricted cash	230,000		230,000
Cash, cash equivalents and restricted cash at end of period	$ 4,961,000	$ 3,568,000	$ 4,961,000	$ 3,568,000